Konu "Hairy Cell Leukemia" için Tıp Fakültesi listeleme
Toplam kayıt 2, listelenen: 1-2
-
Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia
(CIG Media Group, 2020)Objective: The management of R/R-HCL is not standardized yet. Patients with HCL universally harbor BRAF mutations, which makes BRAF inhibitors a potential treatment approach. The effi cacy and safety of the BRAF inhibitor ... -
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
(2024)Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. ...